1. Home
  2. GBIO vs SDST Comparison

GBIO vs SDST Comparison

Compare GBIO & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • SDST
  • Stock Information
  • Founded
  • GBIO 2016
  • SDST 2022
  • Country
  • GBIO United States
  • SDST United States
  • Employees
  • GBIO N/A
  • SDST N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • SDST Blank Checks
  • Sector
  • GBIO Health Care
  • SDST Finance
  • Exchange
  • GBIO Nasdaq
  • SDST Nasdaq
  • Market Cap
  • GBIO 29.2M
  • SDST 33.1M
  • IPO Year
  • GBIO 2020
  • SDST N/A
  • Fundamental
  • Price
  • GBIO $0.38
  • SDST $0.62
  • Analyst Decision
  • GBIO Strong Buy
  • SDST Buy
  • Analyst Count
  • GBIO 4
  • SDST 2
  • Target Price
  • GBIO $7.33
  • SDST $1.70
  • AVG Volume (30 Days)
  • GBIO 476.6K
  • SDST 959.2K
  • Earning Date
  • GBIO 05-07-2025
  • SDST 05-14-2025
  • Dividend Yield
  • GBIO N/A
  • SDST N/A
  • EPS Growth
  • GBIO N/A
  • SDST N/A
  • EPS
  • GBIO N/A
  • SDST N/A
  • Revenue
  • GBIO $24,556,000.00
  • SDST N/A
  • Revenue This Year
  • GBIO N/A
  • SDST $4,114.37
  • Revenue Next Year
  • GBIO N/A
  • SDST N/A
  • P/E Ratio
  • GBIO N/A
  • SDST N/A
  • Revenue Growth
  • GBIO 146.47
  • SDST N/A
  • 52 Week Low
  • GBIO $0.32
  • SDST $0.41
  • 52 Week High
  • GBIO $3.65
  • SDST $28.38
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 45.45
  • SDST N/A
  • Support Level
  • GBIO $0.37
  • SDST N/A
  • Resistance Level
  • GBIO $0.41
  • SDST N/A
  • Average True Range (ATR)
  • GBIO 0.03
  • SDST 0.00
  • MACD
  • GBIO 0.00
  • SDST 0.00
  • Stochastic Oscillator
  • GBIO 28.93
  • SDST 0.00

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About SDST Stardust Power Inc. Common Stock

Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).

Share on Social Networks: